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Abstract
Recent investigations have expanded our knowledge of the regulatory bone marrow (BM) niche,
which is critical in maintaining and directing hematopoietic stem cell (HSC) self-renewal and
differentiation. Osteoblasts, mesenchymal stem cells (MSCs), and CXCL12-abundant reticular
(CAR) cells are niche components in close association with HSCs and have been more clearly
defined in immune cell function and homeostasis. Importantly, cellular inhabitants of the BM
niche signal through G protein-coupled surface receptors (GPCRs) for various appropriate
immune functions. In this article, recent literature on BM niche inhabitants (HSCs, osteoblasts,
MSCs, CAR cells) and their GPCR mechanistic interactions are reviewed for better understanding
of the BM cells involved in immune development, immunologic disease, and current immune
reconstitution therapies.
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Defining the bone marrow niche
In 1961, Till and McCulloch described the proliferative capacity in vivo of normal adult
mouse bone marrow (BM) cells by counting gross nodules in the spleen of an irradiated
recipient [1]. Till and McCulloch proposed that each spleen colony may be derived from one
cell of “clonal origin” that microscopically resembles hematopoietic cells. This theory was
later experimentally demonstrated in 1963 and is the foundation of the modern Colony
Forming Unit Spleen assay (CFU-S) [2]. Five years later, Friedenstein et al. observed
suspended BM cells could form colony fibroblasts from single cells [3]. Collectively, these
studies strengthened the concept of proliferative hematopoietic [1, 2, 4, 5] and fibroblastic
stromal cells [3, 6–11] residing in the BM. In 1978, Schofield proposed that stem cells
associate with other cells to determine future behaviors, coining these stem cell interactions
as a “niche” [12, 13]. Together, these observations and their aforementioned advancements
established a foundation to propel future investigations that have since revealed the cellular
complexity of niche inhabitants and interactions, critical to hematopoiesis.
Clinical and historical relevance: Transplantation
There has been extensive research exploring various hematopoietic cell transplantation
methods and the importance of human leukocyte antigen (HLA) typing. These topics have
been reviewed elsewhere and will not be the focus of this review. However, distinct and
consistent terminology identifying each type of transplantation method is vital for
communication and to move the field forward. Therefore, for this review, hematopoietic cell
transplantation (HCT) will refer to the collection and transplantation of whole BM as a
hematopoietic stem cell (HSC) source, whereas hematopoietic stem cell transplantation
(HSCT) will refer to transplantation of either BM collection for HSC purification or
peripheral blood collection for mobilized HSCs from BM. In addition, autologous (same
donor and recipient) and allogeneic HSCT (same species, different donor and recipient) are
two different graft or donor transplants that may play roles in the success of patient
outcomes. Allogeneic transplantation may involve inadvertent transplantation of donor T
lymphocytes along with beneficial HSCs from the peripheral blood, which can elicit graft-
versus-host disease (GvHD), causing treatment complications. Further investigation into the
complexity of the BM niche could contribute to the development of an improved
transplantation model system that efficiently reconstitutes the immune system, reduces
adverse effects to the patient, and alleviates disease.
The concept of HCT was developed in the 1950s by E. Donnall Thomas when his research
investigations revealed human BM cell infusions could repopulate the BM and create new
blood cells. Dr. Thomas performed the first successful marrow graft transplant in 1959
between monozygotic twins, of which one twin was diagnosed with refractory leukemia
[14]. In 1968, Robert Good and colleagues performed the first successful non-malignancy
HCT from a sibling to treat immune deficiency in an infant brother [15]. Dr. Thomas and
colleagues then performed their first HCT using a HLA-matched sibling donor in 1969 [14].
HCT became standard of care over the next several decades as an approach to address
multiple forms of malignant and non-malignant diseases [16]. Recently, an extensive global
study involving investigations of 72 countries reported an increase in HCT from 46,563 in
2006 to 51,536 in 2008 [17], as an approach to treat malignancies, as well as immune
deficiency, autoimmunity and hereditary diseases [16, 18, 19].
Further advancements in BM niche investigations and transplantation studies have revealed
the importance of specific proliferative cell populations—the BM stem cells. Research
efforts began to focus on the stem cell populations of HCT, which created an HSC selection
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transplantation model. HSCT commonly involves an administration of a stimulating factor
that releases BM HSCs into the blood to ease the collection for transplantation use.
However, HSCT is a high cost, specialized procedure that is still associated with significant
morbidity and mortality [20], including GvHD when allogeneic donors are used. HSCT is
also associated with variable patient immune reconstitution outcomes due to multiple
factors, such as HLA matching, major histocompatibility (MHC) region variations, and
genetic factors that may affect immune responses [21]. Interestingly, it has been shown that
transplantation of mobilized HSCs in peripheral blood fuels immune reconstitution more
efficiently than HSC from the BM [22], allowing for faster hematopoietic recovery, shorter
hospital stays, and similar early survival outcomes [23]. Recent findings in a worldwide
study show peripheral blood was used as a source for stem cells in 98 % of autologous
transplants and 64 % of allogeneic transplants, whereas BM was used as a source of stem
cells in 2 % autologous transplants and 26 % allogeneic transplants [17].
HCT is utilized to treat multiple forms of cancer and hereditary diseases, while specialized
HSCT is also a potential treatment under continuous refinement. Interestingly, Jansen et al.
in 2005 suggested that specific diseases and their stages may direct the sources of cells for
transplantation (ie: HCT vs. HSCT). Patients with “good-prognostic” leukemia may more
readily benefit from HCT, whereas the preferred therapy for patients with high-risk disease
may be HSCT from mobilized HSCs [22]. This suggests that transplant therapy may differ
in approach and stem cell source depending on the disease and its prognosis. For example,
clinical studies by Mancardi investigated HCT (with no specific stem cell selection) for
treatment of an autoimmune disease, multiple sclerosis, which showed promising results of
decreased relapses and active lesion load by MRI [24, 25]. Whereas recent clinical trials are
investigating utilization of HSCT for treatment of another autoimmune disease, systemic
sclerosis (SSc)/scleroderma, clinically characterized as an excessive accumulation of
collagen in skin and organs resulting from vasculopathy, inflammation, and fibrosis with
few therapeutic options [26, 27]. HSCT results show improved skin and functional abilities
as well as long-term survival; however, the benefit of HSCT in comparison to the risk of
adverse effects and HSCT-related mortality (6–10 %) is still under critical evaluation [27].
There is also research investigating the use of mesenchymal stem cells (MSCs) in over 200
small clinical trials for therapeutic effects on hematopoietic malignancies, GvHD, bone
repair, myocardial infarction, Alzheimer’s/Parkinson’s, liver cirrhosis, and several
autoimmune diseases [28]. It has been expected that infusion of allogeneic MSCs would
initiate an immune response, but interestingly MSC transplantation to our knowledge has
shown no adverse events [28], suggesting they may be immune-privileged. In pre-clinical
non-human primate studies, co-transplantation of MSCs improved engraftment of HSCs
after autologous HCT [29]. However, precise identification of cellular and molecular
interactions among MSCs and HSCs remains relatively undefined.
Extensive research efforts for technological and biological advancements have been put
forth to better define and understand the BM niche and stem cells involved in immune
development, immunologic disease, and current immune reconstitution therapies. The
overall goal of this article is to define regions of the BM niche, describe key BM inhabitants
and their mechanistic interactions, and address how targeting such inhabitants or interactions
may serve as therapeutic strategies.
Key inhabitants of the bone marrow niche
Hematopoietic stem cells
HSCs are the most primitive cells within the BM that give rise to myeloid lineage-derived
blood cells (neutrophils, monocytes, basophils, eosinophils, erythrocytes, and
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megakaryocytes), and lymphoid lineage-derived immune cells (natural killer, NK, cells and
T/B lymphocytes). HSCs are predominantly found in the BM, though a limited number may
also be found in the peripheral blood. HSCs have the ability to migrate into the peripheral
blood during stress responses, such as during inflammation or bleeding [30, 31]. Thus, the
self-renewal, multipotency, and mobility properties of HSCs can be utilized for therapeutic
applications.
Irving Weissman and colleagues described the phenotypic characteristics of undifferentiated
human HSCs as having a lack of markers indicative of specific lineage commitment, termed
lineage marker negative (Lin−). Human Lin− HSCS have additional surface expression of
markers CD34, CD90/Thy1, yet low to negative expression of CD38 and CD45RA [32].
Mouse Lin− HSCs were defined as Sca-1+, c-Kit+, Slamf1+, and with negative expression
of CD34 and Flk-2 [32]. Some HSCs are thought to remain dormant to preserve a long-term
self-renewal population pool in the BM niche, whereas other HSCs actively self-renew to
aid in the maintenance of hematopoiesis [33]. In specific, dormant Lin− Sca1+ c-Kit+,
CD150+CD48−CD34− HSCs may give rise to the more active CD34+ HSCs [34].
Osteoblasts
Osteoblasts are responsible for bone formation via synthesis, deposition, and mineralization
of extracellular matrix and reside at the endosteum and medullary cavity interface within the
BM. Osteoblasts have been shown to support immature HSC expansion in vitro and secrete
multiple factors to regulate HSC activity [35, 36]. In addition, increased number of
osteoblasts, via constitutively activated parathyroid hormone (PTH) receptor, correlated with
an increased number of HSCs in vivo [37]. A simultaneous study reported an increase in
spindle-shaped N-cadherin+CD45− osteoblastic (SNO) cells lining the bone surface
correlated with an increase in HSCs and proposed long-term HSCs associate with SNO cells
[38]. Regulation of HSC proliferation and function by osteoblasts in a subregion of the BM
niche was further shown in studies that investigated the removal of osteoblasts, which
correlated with reduced BM cellularity and 3- to 10-fold reductions in HSCs [39]. Although
collective data support osteoblasts as key components in the BM niche, specific interactions
between HSCs and progenitor cells remain an area of heavy investigation.
Mesenchymal stem cells
BM-derived MSCs are “stromal-like” cells that are multipotent, self-renewing precursor
cells that can differentiate into adipocytes, osteocytes, and chondrocytes [40]. Studies have
focused on characterization of these MSC subpopulations with the hope to better define and
understand their biological activity and therapeutic potentials.
Evaluation of BM MSC cell markers have been reviewed for both human and mouse [28], as
various MSC phenotypes have been reported. Human CD146+CD45− [41] and mouse
Nestin+CD45−CD31− MSCs [42] demonstrate stem cell activity by CFU-fibroblast sphere
formations and in vivo self-renewal. A recent investigation utilized an extensive flow
cytometry screening panel to show mouse MSCs highly express 13 markers [43], in which 3
novel MSC markers were identified to differentiate between distinct subtypes of MSCs.
CD200 was characteristic for osteogenic MSCs; SSEA4 and CD140a were expressed on
adipogenic progenitors [43]. Similarly, an extensive screening of human MSCs markers
were investigated from 53 donors of diverse age and sex. Results showed younger donors
had increased expression of 7 markers, including CD146; younger female donors possessed
a more frequent and rapidly proliferative clonogenic MSC population; and mesodermal
differentiation was unaffected by donor age or gender [44]. Overall, these investigations
touch upon the MSC phenotypes within the BM niche. With continued research, a better
understanding and utilization of defined MSC subpopulations and their functional
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properties, as well as potential donor-related effects, may enhance stem cell therapy patient
outcomes.
CXCL12-abundant reticular (CAR) cells
In 2006, work from the Nagasawa laboratory identified a unique, small population of
reticular cells with long processes that were uniformly dispersed in mouse BM. These
reticular cells secreted high levels of CXCL12, and thus were termed CXCL12-abundant
reticular (CAR) cells. CAR cells surround the sinusoidal endothelial cells [45, 46] in
association with CD150+CD48−CD41− HSCs, early B cell precursors and plasma cells [47–
50], plasmacytoid dendritic cells [51] and NK cells [52] in the perivascular niche. CAR cells
express VCAM-1, CD44, and PDGFRα/β and do not express surface makers Sca1, CD45, or
CD31 [47]. The human equivalent of mouse CAR cells are currently thought to be the
subendothelial cells with CD146 expression [41].
Disruption of the CAR cell population alters the steady state and HSC populations within
the BM niche. Selective depletion of CAR cells reduced the adipogenic and osteogenic
differentiation ability of BM cells, reduced the size and number of HSCs, and reduced B cell
and erythroid progenitors, but no immediate effects on osteoblasts and endothelial cells were
observed [53]. These and other data further confirm CAR cells may be required for
proliferation and maintenance of HSCs, B cells, and erythroid progenitor cells [47, 53].
Interestingly, studies by Visnjic et al. and Zhu et al. of osteoblastic lineage cell depletion
also demonstrated a reduction in both erythroid progenitors and B cells [39, 54]. Therefore,
while depletion of niche components has been shown to alter steady state BM niches, the
specific cells, interactions, and locations of immune development may need to be further
defined within the BM niche.
In summary, collective data suggest HSCs, osteoblasts, MSCs, and CAR cells participate in
the intricate complexity of BM niche interactions during immune cell development and may
serve as vital components for clinical therapeutic strategies.
Functional regions of the bone marrow niche
Endosteal and perivascular niche
Immune cell development takes place within a regulatory BM niche that has been
conceptually divided into two main functional regions, the endosteal and perivascular niche.
HSCs, MSCs [28], CAR cells [46], and osteoblasts [37] have all been implicated as key
components in these functional regions. The endosteal niche resides at the endosteum and
medullary cavity interface within the BM where historically osteoblasts are thought to
sustain HSC quiescence, whereas the microenvironment of sinusoidal vessels surrounded by
endothelial cells and subendothelial stromal cells comprise the perivascular BM niche. It is
thought that HSCs preferentially associate with the perivascular region [55] due to nearby
stromal CAR cells, which readily secrete a key chemoattractant chemokine CXCL12. HSCs
and CAR cells are nestled within the perivascular niche with a self-renewing MSC
population identified by the presence of an intermediate filament protein, Nestin [56].
Nestin-positive MSCs have been linked to influence HSC migration and maintenance [42].
A vexing question lingers as to whether particular immune cells or certain developmental
stages are specific to specialized compartments, as opposed to sharing one common BM
niche. This was highlighted in two recent and simultaneously released studies. Ding and
Morrison demonstrated the diverse effects on various HSC or progenitor cell populations
during controlled CXCL12 deletion studies [57]. Selective CXCL12 deletions in osteoblasts
within the endosteal niche showed depletion of only early lymphoid progenitors. In contrast,
depletion of CXCL12 in perivascular niche endothelial and perivascular stromal cells
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demonstrated depletion of HSCs. Depletion of perivascular stromal cells also depleted
specific progenitors and forced egression outside the BM. This study suggests distinctive
stem and progenitor cell subsets reside in specific BM niches. Specifically, early lymphoid
progenitors [57] and long-lived, dormant HSCs [58] may more readily occupy the endosteal
niche, whereas the perivascular niche may more readily house active HSCs [58]. Greenbaum
et al. also reported CXCL12 deletion studies and concluded similar findings of osteoblastic
and CAR cells support B-lymphoid progenitor cells and retain hematopoietic progenitor
cells (HPCs), whereas the perivascular niche supports HSCs [59].
Interesting new data implicate megakaryocytes as an additional component of the HSC
niche that may regulate HSC proliferation through cytokine release of IGF-1 and IGFBP-3
[60]. Neuronal/glial cells, adipocytes, osteoclasts, and monocytes/macrophages have also
newly demonstrated roles in the BM niche, though these have been reviewed elsewhere and
are beyond the scope of this particular review [61]. In summary, recent data strengthen the
concept of distinct functional regions within the BM that house specific developmental
stages of immune cell development (Fig. 1), and additional subregions may be defined by
future studies.
G protein-coupled receptor (GPCR) molecular interactions within the bone
marrow niche
Overview
G protein-coupled receptors (GPCRs) consist of seven transmembrane domains that elicit
intracellular signaling upon extracellular ligand stimulation. Ligand and GPCR interactions
force conformational change and elicit activation of guanine nucleotide binding proteins,
referred to as G proteins [62]. G proteins (α,β/γ) dissociate from the GPCR and initiate
downstream signaling [62]. GPCRs may also signal G-protein independent pathways,
including negative regulation of receptor expression by G protein-coupled receptor kinases
(GRKs) [62]. GPCRs encompass 3–5 % of the human genome and play vital roles in various
physiological functions, serving as ideal therapeutic targets. In fact, 20–50 % of market
pharmaceuticals focus on GPCR targeting [40].
One area of GPCR signaling is to elicit fundamental processes for immune development and
function [40]. Without these interactions, cellular survival, proliferation, differentiation, or
trafficking may be severely compromised. This review focuses on three particular GPCRs
that have been implicated in BM immune cell function: PTH-receptor, CXCR4, and
sphingosine-1-phosphate receptor (S1PR).
PTH/PTH-receptor signaling
Parathyroid hormone (PTH) is released from parathyroid glands and binds PTH-receptor
(PTH1R), a G protein-coupled receptor on cells of the osteoblast lineage, whereby
mechanisms have been extensively reviewed [63]. The Calvi laboratory has highlighted the
importance of PTH in the BM niche as PTH/PTH1R ligation elicits HSC expansion in vitro
and in vivo with increased survival after HCT during pre-clinical trials [37, 64]. In addition,
patients with hyperparathyroidism produce excess PTH and have been shown to have an
increase in HSC mobilization [65, 66]. However, when PTH signaling was constitutively
activated in osteocytes or fully differentiated osteoblastic cells, the number of HSCs and
function remained unchanged, suggesting that kinetics of PTH stimulation are critical [65,
67].
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There are 4 distinct classes of chemokines and receptors, defined by their structural terminal
cysteine residues that determine function and ligand-receptor binding: CC, CXC, XC, and
CX3C chemokines, which bind to their respective CCR, CXCR, XCR, and CX3CR
receptors with redundancy and promiscuity [68]. CXCR4 is a unique chemokine receptor
since it exclusively binds CXCL12 [69]. CXCR4 is expressed on HSCs, mature leukocyte
subsets including monocytes, neutrophils, T-lymphocytes, and B-lymphocytes [70], and a
small subset of MSCs [71, 72]. CXCR4 ligation of CXCL12 is a vital signaling mechanism
for immune cellular development in the BM niche by eliciting a signaling cascade to
regulate leukocyte survival, proliferation, chemotaxis, and egress from the BM [73]. In
leukocytes, CXCR4 signaling is negatively regulated by phosphorylation of its C-terminus
tail via a G protein-coupled receptor kinase (GRK). GRKs trigger GPCR receptor
internalization by recruiting β-arrestin and uncoupling the receptor from G-proteins [74].
If the CXCL12/CXCR4 signaling cascade is dysregulated, it may lead to abnormal receptor
desensitization and internalization causing a gain-of-function in CXCR4, now well
characterized as WHIM syndrome (Warts, Hypogammaglobulinemia, Infection, and
Myelokathexis). In WHIM, excessive signaling through CXCL12/CXCR4 leads to retention
of leukocytes in the BM (myelokathexis) and fewer circulating mature leukocytes in the
blood necessary to protect the individual from infection [75, 76]. GRK-3 appears to have
selective regulation of CXCR4 demonstrated both in vitro biochemically and in vivo
biologically with clinical patients [76, 77]. Recent work by Tarrant et al. has confirmed that
GRK-3 deficiency in mice impairs CXCL12/CXCR4 responses and demonstrates
myelokathexis and hypogammaglobulinemia mirrored in WHIM syndrome [78]. GRK-3-
deficient mice specifically demonstrate hypercellularity of the BM with retention of GR-1hi
CD11bhi myeloid cells [78]. The GRK-3-deficient mouse model represents a clinical
immunological disease manifestation of a subset of WHIM syndrome and allows an ideal
model system to further investigate the inhabitants and interactions of hematopoiesis in the
BM niche.
S1P/S1PR signaling
Sphingosine-1-phosphate (S1P) ligands are active phospholipids thought to be produced by
mature red blood cells [79, 80], endothelial cells [81–83], and platelets [84]. S1P has vast
physiological roles, one of which is a chemoattractant for HSCs. S1P is expressed with low
levels in the BM and tissues and high levels in peripheral blood to thus stimulate HSC
trafficking [85], in which the S1P levels are controlled by S1P lyase, an enzyme
ubiquitously expressed that irreversibly degrades S1P [86]. HSCs express a subset of GPCR
sphingosine-1-phosphate receptors 1–5 (S1PR1–5) that bind S1P ligands. S1PR-1 has been
shown to be expressed on immature and committed progenitor mouse BM cells, whereas
S1P3 and S1P5 are expressed mostly on immature progenitors, and S1P2 and S1P4 are
expressed on committed progenitors [87, 88].
S1P has also been shown to be involved in MSC recruitment and differentiation, mediated
through Rho/ERK signaling [89]. A recent novel finding by Zhang et al. implicates S1P/
S1PR signaling axis as a vital BM mechanism to also direct elongation of megakaryocytic
pro-platelet extensions into BM sinusoids, creating shedding of platelets [90]. This novel
finding implicates S1P/S1PR signaling in the BM niche as a master regulator of
thrombopoiesis, and suggests the S1P/S1PR interaction may be a potential therapeutic target
for patients with thrombocytopenia. In fact, dysregulation of S1P correlates with progression
of various diseases, such as cancer, atherosclerosis, diabetes, and osteoporosis [91]. Partial
deletion or inhibition of S1P lyase has also been implicated as a potential therapeutic target
for autoimmune disease, such as rheumatoid arthritis and multiple sclerosis, since reduction
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in S1P lyase activity correlated with decreased numbers of circulating lymphocytes [86, 91–
93].
While the vast physiological roles of S1PR in the BM niche are progressively becoming
more defined, the signaling mechanisms are still under active investigation. Recent findings
suggest G protein-coupled receptor kinase-2 (GRK-2) down-regulates S1PR-1 by
desensitization to initiate lymphocytes egress from the circulation into tissues [94].
Moreover, signaling through S1PR-1 and S1PR-3 has been shown to stimulate proliferation
in a β-arrestin-dependent manner in the embryonic stem cell population [95]. These exciting
investigations emphasize the importance of S1PR1-5 in physiological function, particularly
within stem cell and progenitor populations, though a better understanding of the
mechanisms may provide enhanced potential therapeutic targets.
Cross-talk between CXCL12/CXCR4 and S1P/S1PR
Recent work has implicated a cross-talk mechanism between CXCL12 and S1P that may
regulate HSC migration, development, and bone remodeling [87]. Decreasing chemo-
attractant CXCL12 in the BM and increasing S1P in the blood may control how quiescent
HSCs shift to a migratory and differentiating phenotype. A pre-clinical study by Golan et al.
has shown that disruption of S1P signaling decreased HSC and progenitor cell egress by
inhibition of CXCL12 release. S1P has been shown to induce CXCL12 secretion from BM
stromal cells (Nestin+ MSCs) in a reactive oxygen species (ROS) signaling-dependent
manner. CXCL12 is then released into the circulation to further elicit cell mobilization.
Increased S1P levels in the BM have also been shown to increase ROS production in HSCs,
suggesting S1P/S1PR signaling mechanism that regulates progenitor cell egress via ROS
signaling in HSCs and MSCs with enhanced CXCL12 secretion [87, 96].
Bone marrow niche therapeutic targeting strategies
Retention signaling
The BM hematopoietic system is typically in a steady state of HSC maintenance with low-
level release of HSCs from the BM into the circulation, serving as a sustaining role to
replenish the immune system. HSCs are more readily released from the BM upon
hematopoietic stresses, such as exercise or infection [97]. By disrupting “retention signals”
with stimulating factors in the BM niche, studies have revealed that HSCs are retained
within the BM in part by GPCR signaling, chemotactic gradients, and cellular interactions.
Well-studied retention signals include CXCL12/CXCR4 signaling interactions (described
above) and VCAM1 (on MSCs [43] and CAR cells [47])/VLA-4 (on HSCs) adhesive
interactions; however, there is also evidence supporting S1P/S1PR interactions, all of which
have been recently reviewed [98]. Taken together, these signaling interactions between
HSCs and other BM niche cells have been utilized as targets of current stem cell
therapeutics to disrupt retention and force HSC egress from the BM to rapidly fuel immune
reconstitution.
Granulocyte colony-stimulating factor (G-CSF) treatment
Administration of G-CSF analogues (also known as Neupogen or filgrastim) has been
shown to increase BM cellularity in combination with enhanced egress of mature and
immature BM cells, including HSCs [97]. Therefore, G-CSF has been used clinically for
HSC mobilization [97, 99]. It has been suggested that G-CSF partially acts as an HSC
mobilizer by inducing protease activity in the niche, which cleaves VCAM, thus disrupting a
vital retention mechanism [98, 100]. G-CSF has also been shown to down-regulate and
cleave CXCL12, which affects CXCR4 ligation for retention signaling [98, 101]. However,
due to further studies, a more complex model of G-CSF mechanism has emerged that
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suggests the protease-dependent and protease-independent decrease in CXCL12 mRNA and
protein expression in the BM may elicit HSC mobilization [102]. Interestingly,
administration of G-CSF has also been shown to increase S1P signaling in the BM in a P13-
kinase-dependent manner [87], suggesting that further studies are warranted to better
understand the seemingly complex mechanism of G-CSF treatment.
GPCR antagonist therapies
AMD3100
Plerixafor, also more commonly known as AMD3100, is used as a CXCR4 antagonist that
blocks the CXCL12/CXCR4 signaling mechanism within the BM niche, forcing egress of
HSCs into the periphery [103]. A phase III clinical trial study reported that participants who
were treated with HSC mobilization by AMD3100 and G-CSF had a significantly higher
CD34+ cell count than those who were mobilized with just G-CSF alone [104]. The FDA
has since approved AMD3100 for use in combination with G-CSF for mobilization of HSCs
in adults, specifically with non-Hodgkin’s lymphoma [105] or multiple myeloma [106], for
immune reconstitution.
AMD3100 has also been implicated in cancer therapeutics for reduction of tumor
proliferation, impaired cell survival, and induction of differentiation, particularly in acute
myeloid leukemia human cells [107]. Kang et al. demonstrated AMD3100 treatment post-
HSCT significantly improved animal survival, enhanced donor cell engraftment, and
supported recovery of myeloid and lymphoid lineages [108]. To date, there are 69 clinical
trials worldwide investigating AMD3100 treatment on various malignancies. There are
currently 12 clinical trials investigating AMD3100 for use in treatment of non-malignant
diseases, and 20 clinical studies investigating AMD3100 in other transplantation models
(Table 1).
In immune deficiency, AMD3100 has been investigated in phase I clinical trials as a
CXCR4 antagonist for the treatment of WHIM syndrome. Treatment of WHIM patients
demonstrated leukocytosis and restored neutrophil and B lymphocyte numbers into the
circulation [109]. In summary, AMD3100 holds therapeutic potential for the treatment of
malignancies and hereditary diseases, including immune deficiency (Table 1).
GPCR agonist therapies
PTH treatment
PTH signaling has been investigated as a potential therapy to facilitate stem cell
mobilization and engraftment. PTH administration for stem cell mobilization has been
explored in phase I clinical trials as a follow-up to pre-clinical studies demonstrating
enhanced survival with PTH administered after transplantation [110]. In 20 patients, PTH
was well tolerated with no dose-limiting toxicities and showed adequate CD34+ stem cell
mobilization [110]. Although further phase II clinical trials of 13 patients showed
engraftment, 38.5 % of patients experienced GvHD leading to four deaths and premature
study termination [111]. To our knowledge, there are no current on-going clinical trials
evaluating a potential therapeutic model of PTH in stem cell mobilization.
FTY720 and SEW2871 treatments
In addition to synergistic interactions between CXCR4 and G-CSF signaling, cross-talk
pathways between CXCR4 and S1PR have also been shown to enhance HSCs migratory
response [88, 112]. Thus, targeting CXCR4, S1PR, and cross-talk of CXCR4 and S1PR
signaling mechanisms in the BM niche may serve as therapeutic strategies.
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Treatment using the S1P1R agonist FTY720 (fingolimod) binds and initiates receptor
internalization and degradation and leads to S1P/S1PR signaling suppression. As a result,
FTY720 treatment reduces the number of HSCs in peripheral blood [113] and leads to
retention of T [114, 115] and B lymphocytes [116, 117] in pre-clinical mouse studies. Golan
et al. reported that FTY720 treatment reduced HSC mobilization into the circulation through
S1P1R desensitization and inhibition of CXCL12 secretion from mesenchymal stromal cells.
These data suggest cross-talk between S1P and CXCL12 to direct MSC and HSC
mobilization [96]. Therefore, these collective data strongly suggest that S1P/S1PR
molecular signaling, as well as CXCL12/CXCR4 interactions, are vital for HSC, progenitor,
and mature cell mobilization and egress from the BM.
Combination therapy of CXCR4 antagonists with S1PR agonists have been investigated as
possible therapeutic targets. When AMD3100 treatment was accompanied with S1PR
agonist SEW2871, which recycles the S1PR receptor, HSC and progenitor mobilization was
significantly enhanced. In contrast, SEW2871 alone had no effect on increasing HSC
mobilization into the blood [118]. Therefore, combination therapy of AMD3100 and
SEW2871 showed synergistic therapeutic benefits in pre-clinical models [118], but
SEW2871 remains to be tested in humans [85]. However, when AMD3100 was
administered with another S1PR agonist, FTY720 (fingolimod), which internalizes and
degrades S1PR, immune mobilization was suppressed [96]. Therefore, while agonist
FTY720 has been more extensively studied and already clinically used (Table 2), it typically
sequesters cells for limited BM release by S1PR degradation and may not be best suited in
combination with AMD3100 for immune reconstitution therapy.
Conclusions
Past and recent studies of the BM have collectively provided a greater understanding of the
molecular interactions among the vital inhabitants of the niche. Applications of this
knowledge have enhanced therapeutics in the clinical setting for transplantation of
malignancy and non-malignant diseases of autoimmunity and immune deficiency. Future
investigations of mechanistic GPCR intracellular signaling and utilization of receptor
agonist/antagonist interactions in the BM niche are warranted. With further investigations
and collaborative studies, the field of stem cell therapy will continue to advance toward the
treatment of human disease.
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Figure 1. The bone marrow niche
Long-lived, dormant hematopoietic stem cells (HSCs) associate with osteoblasts to sustain
quiescence in the endosteal niche and serve as the primitive cell “reservoir” within the bone
marrow (BM). HSCs that reside within the perivascular niche associate with Nestin-positive
mesenchymal stem cells (MSCs) and CXCL12-abundant reticular (CAR) cells that secrete
CXCL12 to influence HSC maintenance and activity by either retaining cells within the BM
or allowing cells into circulation, which may be impacted by the balance and regulation of
CXCL12/CXCR4 and S1P/S1P1R.
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Table 1
Clinical trial investigations utilizing AMD3100
Clinical investigations of AMD3100 No. of studies Key references
Non-malignant diseases
 Immune deficiency 3
  Myelokathexis/neutropenia 1 McDermott 2011 [119]
  WHIM syndrome 1 Dale 2011 [109]
  Severe combined immunodeficiency 1
 Autoimmune disease 1 Song 2010a [120]
  Scleroderma 1 Makino 2013a [121]
 Hereditary diseases 3
  Beta-thalassemia 1 Yannaki 2012 [122]
  Fanconi anemia 2 Pulliam 2008a [123]
 Other 5
  Myelodysplastic syndrome 1
  Diabetic ulcer 1 Nishimura 2012a [124]
  Renal impairment 1 MacFarland 2010 [125]
  COPD/cystic fibrosis/pulmonary fibrosis 1
  End-stage liver fisease 1
Malignant diseases
 Hematological neoplasm/malignancy 66
Uy 2012 [126]
Devine 2004 [103]





 Acute myeloid leukemia 11
 Plasma cell/multiple myeloma (MM) 13
 Lymphoma
  Non-Hodgkin’s 9
  Hodgkin’s 2
  Unspecified 3
 Chronic lymphocytic leukemia and/or small 2
 lymphocytic lymphoma (unspecified) and MM 9
 Non-Hodgkin’s lymphoma and MM 7
 leukemia and myelodysplastic syndrome 5
 Unspecified 5
 Solid tumor neoplasm/malignancy
 Glioma 3 Rubin 2003a [131]
 Ewings sarcoma/soft tissue 2 Redjal 2006a [132]
 Sarcoma/neuroblastoma 1 Vives 2012a [133]
Transplantation 20
 Autologous/allogeneic stem cell Transplantation 9
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Clinical investigations of AMD3100 No. of studies Key references
 Mobilization (healthy donor) 9 Devine 2008 [134]
 Mastocytosis (mast cell release) 1 Shepherd 2006 [135]
 Safety/efficacy subcutaneous administration 1
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Table 2
Clinical trial investigations utilizing FTY720
Clinical trial investigations of FTY720 No. of Studies Key references
Autoimmune and inflammatory fiseases 46 Kappos 2006 [136]
 Multiple sclerosis Kappos 2010 [137]
  Primary progressive 2 Comi 2010 [138]
  Relapsing, remitting 22 O’Connor 2010 [139]
  Non-specified 18






 Acute demyelinating optic neuritis 1
 Asthma 1
Neurological disease/disorder 2





 Renal insufficiency 1
Other 1
 Cardiac/pulmonary function 1 Schmouder 2012 [146]
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